Johnson & Johnson talcum powder has been linked to cases of ovarian cancer and, according to lawsuits and at least one major jury verdict, the company knew of the carcinogenic association for years but failed to warn customers of the risks.

In one recent trial, a jury handed down a $72 million verdict for a woman who died of ovarian cancer after using the company’s talcum products for years.

If you or a loved one developed ovarian cancer after long-term use of J&J Baby Powder or Shower to Shower talc brands, you may have a legal claim and you should contact our experienced attorneys at Kline & Specter, PC.

Our law firm, based in Philadelphia, PA, and handling cases nationwide, has more than 40 attorneys, five of whom are also doctors, and has had great success litigating cases involving health issues and faulty products. We also have won major cases against large corporations, including recent verdicts against J&J of $13.5 million and $12.5 million in transvaginal mesh trials.

The recent verdict against J&J over its talcum powder products represented the first time the world’s largest maker of health-care products was ordered by a jury to pay damages over claims that it failed to warn customers of a cancer risk despite knowing for decades that its talc-based products were suspected carcinogens. J&J currently is facing about 1,200 suits claiming a link between its talc products and ovarian cancer.

Shower to Shower was advertised in the late 1980s as a feminine hygiene product. In 1999, the American Cancer Society advised women to use corn starch-based products in the genital area instead of talcum. (Shower to Shower was bought in 2012 by Valeant Pharmaceuticals International Inc., which was not a defendant in the recent trial.)

Kline & Specter handles litigation in Pennsylvania, New Jersey, Delaware and nationwide. In the recent cases over J&J’s transvaginal mesh, Shanin Specter won verdicts for two women, one in New Jersey and one in Indiana, who suffered permanent pain during sexual intercourse after the plastic-like product eroded in their bodies and could not be completely removed with additional surgeries.

In other recent litigation against Johnson & Johnson, Tom Kline won verdicts of $2.5 million and $500,000 for young men who suffered abnormal breast growth, a condition known as gynecomastia, after taking the company’s anti-psychotic drug Risperdal. Kline & Specter is currently teamed with two other law firms in representing some 8,000 victims of Risperdal, manufactured by J&J subsidiary Janssen Pharmaceuticals.